GE Healthcare, Dyax enter agreement for imaging peptides for use in cancer research

GE Healthcare, a unit of GE (NYSE:GE; Chalfont St. Giles, England), and Dyax Corp. (NASDAQ:DYAX; Burlington, MA) entered into a licensing agreement for the development and commercialization of peptides binding to c-Met, which provides upfront, milestone, and royalty payments to Dyax. Research of potential diagnostic applications and use as a patient selection biomarker in oncology will be explored by GE Healthcare in collaboration with academic institutions and pharmaceutical companies. The license includes application of the peptides in optical imaging, as well as in positron emission tomography (PET) and single proton emission computed tomography (SPECT).

“Growth factor receptors such as c-Met are promising therapeutic targets that could be a critical factor in the development of colorectal, lung, and liver oncology drugs,” says Marivi Mendizabal, head of research, GE Healthcare Medical Diagnostics. “As in-vivo imaging technologies become increasingly important in oncology drug development, our vision is that we will be able to rapidly develop new targeted molecular diagnostics—not just for our own clinical portfolio, but as ‘companion’ diagnostic offerings for our strategic biopharmaceutical partnerships.”

Initial preclinical data on c-Met imaging will be presented by GE Healthcare at the American Academy of Cancer Research meeting March 31 – April 4 in Chicago, IL.


Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow OptoIQ on your iPhone; download the free app here.

Subscribe now to BioOptics World magazine; it's free! 

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

PHOTODYNAMIC THERAPY/CELL BIOLOGY: Luminescent nanoparticle efficient and effective for PDT, cell imaging

While doing research for security-related radiation detection, University of Texas at Arlington physics professor Wei Chen discovered unexplained decreases in the luminescence of a copper-cysteamin...

CANCER TREATMENT/NANOTECHNOLOGY: Light-activated chemotherapy delivery limits side effects

With standard drug-delivery methods, toxic chemotherapy cocktails affect healthy tissue in addition to cancer.

Clinical trial for multibeam OCT system yields positive top line results

Michelson Diagnostics recently completed a multicenter, prospective clinical trial for basal cell carcinoma diagnosis using the company's VivoSight multibeam optical coherence tomography (OCT) syst...

SPECTROSCOPY/BREAST CANCER: Light-emitting cables enable MRI/NIR approach to breast cancer assessment

A new approach that combines magnetic resonance imaging (MRI) with near-infrared (NIR) spectroscopy could spare women with suspicious mammogram results from invasive biopsies to look for tumors.


Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...



Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS